U.S. Markets open in 5 hrs 9 mins
  • S&P Futures

    3,832.25
    +6.75 (+0.18%)
     
  • Dow Futures

    30,989.00
    +56.00 (+0.18%)
     
  • Nasdaq Futures

    11,697.75
    +23.50 (+0.20%)
     
  • Russell 2000 Futures

    1,742.00
    +3.70 (+0.21%)
     
  • Crude Oil

    111.81
    +0.05 (+0.04%)
     
  • Gold

    1,816.90
    -4.30 (-0.24%)
     
  • Silver

    20.81
    -0.06 (-0.30%)
     
  • EUR/USD

    1.0517
    -0.0008 (-0.0736%)
     
  • 10-Yr Bond

    3.2060
    0.0000 (0.00%)
     
  • Vix

    28.54
    +1.59 (+5.90%)
     
  • GBP/USD

    1.2187
    +0.0003 (+0.0219%)
     
  • USD/JPY

    136.1740
    +0.0460 (+0.0338%)
     
  • BTC-USD

    20,120.93
    -757.07 (-3.63%)
     
  • CMC Crypto 200

    435.51
    -14.55 (-3.23%)
     
  • FTSE 100

    7,284.99
    -38.42 (-0.52%)
     
  • Nikkei 225

    26,804.60
    -244.87 (-0.91%)
     

RxSight to Report Third Quarter 2021 Financial Results on November 10, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ALISO VIEJO, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the third quarter of 2021 after the market close on Wednesday, November 10, 2021. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.rxsight.com, on the Investors page in the News and Events section. The call will also be available by dialing 844-602-7038 (U.S.) or 916-637-9714 (International) five to ten minutes prior to the start time, using conference ID: 1239025.

About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens. Additional information about RxSight® can be found at www.rxsight.com.

Investor Relations Contact:
Philip Taylor
Gilmartin Group
415.937.5406
IR@rxsight.com

Company contact:
Roy Freeman
Sr. Director, Marketing
rfreeman@rxsight.com